Somatrem
| Clinical data | |
|---|---|
| Trade names | Protropin |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C995H1537N263O301S8 |
| Molar mass | 22256.26 g·mol−1 |
  (what is this?) (verify) | |
Somatrem, sold under the brand name Protropin, is an analogue of growth hormone (GH).[1]
Somatrem is a recombinant human growth hormone used for the treatment of short stature due to decreased or absent secretion of endogenous growth hormone. Somatrem was first marketed under the brand name Protropin by Genentech in 1985.[2] It differs from endogenous growth hormone by the addition of an extra methionine at the N-terminus[3]. Somatrem has largely been replaced by somatropin, marketed by several companies including by Genentech as the brand Nutropin.
References
- ↑ Flodh H (1987). "Present situation worldwide regarding the use and clinical experience of Somatonorm (somatrem)". Acta Paediatrica Scandinavica. Supplement. 331: 1–4. doi:10.1111/j.1651-2227.1987.tb17089.x. PMID 3300150. S2CID 20410776.
- ↑ "Genentech: Press Releases - Friday, Oct 18, 1985". www.gene.com.
- ↑ Growth hormone therapy#cite note-32
External links
- "Somatrem". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.